Intracameral dexamethasone 9% vs prednisolone acetate 1% in controlling postoperative pain and inflammation in patients undergoing cataract surgery

J Cataract Refract Surg. 2022 Aug 1;48(8):906-911. doi: 10.1097/j.jcrs.0000000000000887. Epub 2022 Jan 18.

Abstract

Purpose: To compare patient preferences of postoperative cataract surgery topical medication use between a 1-drop and a 3-drop regimen.

Setting: Two private cataract surgery centers.

Design: Open-label randomized self-controlled prospective study.

Methods: This study included 30 patients (60 eyes) undergoing routine cataract surgery in both eyes. In this contralateral eye study, 1 eye of each patient was randomized to the 1-drop regimen of intracameral delivery of moxifloxacin and dexamethasone suspension and topical bromfenac for 30 days. The other eye, randomized to the 3-drop regimen, received topical moxifloxacin 0.5% 4 times a day for 7 days and bromfenac 0.07% daily for 30 days postoperatively, along with prednisolone acetate 1% 4 times a day for 30 days. Patients reported their preferred regimen 2 weeks after the second surgery with a validated questionnaire. Secondary outcomes included subjective ocular pain, inflammation score, and out-of-pocket cost. Intraocular pressure (IOP) and macular thickness were also measured.

Results: Of the 29 patients, 28 (96.6%) significantly more preferred the eye treated with a 1-drop regimen. Self-reported pain, activity interference, and out-of-pocket cost were significantly less in the 1-drop group. Inflammation and 1-day uncorrected distance visual acuity were also significantly better in the 1-drop group. Macular thickness and mean IOP were similar between groups.

Conclusions: Intracameral delivery of steroid and antibiotics was preferred by most of the patients undergoing cataract surgery. These eyes had significantly less pain, inflammation, activity interference, and out-of-pocket cost and significantly better uncorrected distance visual acuity at 1 day postoperatively. IOP and macular thickness were similar between groups.

Trial registration: ClinicalTrials.gov NCT04273282.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cataract Extraction*
  • Cataract*
  • Dexamethasone / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Moxifloxacin / therapeutic use
  • Ophthalmic Solutions
  • Pain, Postoperative / drug therapy
  • Pain, Postoperative / prevention & control
  • Phacoemulsification*
  • Postoperative Complications / prevention & control
  • Prednisolone / analogs & derivatives
  • Prospective Studies

Substances

  • Ophthalmic Solutions
  • Dexamethasone
  • prednisolone acetate
  • Prednisolone
  • Moxifloxacin

Associated data

  • ClinicalTrials.gov/NCT04273282